|
1. |
Therapy for Human Immunodeficiency Virus Infection—1989 |
|
Clinical Neuropharmacology,
Volume 13,
Issue 1,
1990,
Page 1-18
Harold Kessler,
Alan Harris,
Preview
|
PDF (1259KB)
|
|
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
2. |
Response to a Standard Oral Levodopa Test in Parkinsonian Patients with and without Motor Fluctuations |
|
Clinical Neuropharmacology,
Volume 13,
Issue 1,
1990,
Page 19-28
M. Contin,
R. Riva,
P. Martinelli,
G. Procaccianti,
P. Cortelli,
P. Avoni,
A. Baruzzi,
Preview
|
PDF (530KB)
|
|
摘要:
The acute dose-response profile of a standard oral levodopa dose was followed, over a maximum 8-h period, in 13 patients with and 10 patients without motor fluctuations using a battery of motor quantitative tests (tapping and walking speed, and multiple choice reaction and movement times). Thirteen age-matched normal controls performed tapping and psychomotor tests, at the same time intervals, over a 4-h period. Tapping test and movement times proved significantly impaired in all patients and were the best indicator of levodopa effect, while walking speed and reaction times were apparently of less value, except in severely affected patients. The duration of the levodopa antiparkinsonian effect differed markedly between the two groups, since fluctuating patients returned to prelevodopa dose values within 4 h (mean ± SEM: 203 ± 16 min), while in the stable group motor scores remained significantly higher than baseline values up to at least 7 h postdose. The magnitude of the effect was similar in the two groups, but response was complicated by mild to severe dyskinesias in 9 of 13 fluctuating subjects. The pharmacokinetic parameters of levodopa were almost identical in the two groups. Our data add further weight to the hypothesis that cerebral pharmacokinetic or pharmacodynamic factors are responsible for motor fluctuations. Oral levodopa doses coupled with objective tests of motor performance may prove a practical clinical tool to assess and optimize the relationship between drug dose and therapeutic effect.
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
3. |
L‐Deprenyl, Levodopa Pharmacokinetics, and Response Fluctuations in Parkinson's Disease |
|
Clinical Neuropharmacology,
Volume 13,
Issue 1,
1990,
Page 29-35
Jesse Cedarbaum,
Mary Silvestri,
Mary Clark,
Amy Harts,
Henn Kutt,
Preview
|
PDF (343KB)
|
|
摘要:
Six patients with Parkinson's disease (PD) and therapeutic response fluctuations (RF) on levodopa treatment participated in an open-label trial of L-deprenyl (Eldepryl) in conjunction with Sinemet. Deprenyl (10 mg/day) allowed a slight but not statistically significant 22% reduction of total daily levodopa intake after 4 weeks of treatment, with a significant but unsustained reduction in the number of daily “off” periods and an increase in the portion of waking day spent “on.” Pharmacokinetic studies revealed no effect of deprenyl on the plasma levodopa concentration vs. time curve, or the coefficient of variation (C.V.) of plasma levodopa levels measured over an 8-h period. Plasma DOPAC levels were unaffected, suggesting that the majority of peripheral DOPAC is generated by action of MAO-A. For most patients, benefit was not maintained. Two patients have continued taking the drug, and both have enjoyed significant reductions in total levodopa dose. Both have mild end-of-dose failure and little dyskinesia. Since no changes in peripheral pharmacokinetics of levodopa could be demonstrated, any therapeutic action of deprenyl in PD would appear to be due to prolongation of dopaminergic activity within the CNS.
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
4. |
Clinically Atypical Expression of Pathologically Typical Lewy‐Body Parkinsonism |
|
Clinical Neuropharmacology,
Volume 13,
Issue 1,
1990,
Page 36-47
Jacob Sage,
Douglas Miller,
Lawrence Golbe,
Arthur Walters,
Roger Duvoisin,
Preview
|
PDF (740KB)
|
|
摘要:
Six patients autopsied by the neuropathology service at UMDNJ—Robert Wood Johnson Medical School between 1985 and 1988 had pathologically typical Lewy-body Parkinson's disease (PD). Review of their clinical records revealed that none had clinically typical PD. Atypical clinical features included juvenile onset, retrocollis, strong family history, and absence of tremor, flexed posture, or levodopa response. One patient had dementia without parkinsonism. We conclude that the clinical spectrum of Lewy-body PD is wider than is generally assumed and that the diagnosis of pathologically typical Parkinson's disease cannot be excluded on clinical grounds alone.
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
5. |
Lack of Cardiovascular Side Effects of the New Tricyclic Antidepressant Tianeptine A Double‐Blind, Placebo‐Controlled Study in Young Healthy Volunteers |
|
Clinical Neuropharmacology,
Volume 13,
Issue 1,
1990,
Page 48-57
Michèle Juvent,
Jacques Douchamps,
Eric Delcourt,
Willy Kostucki,
Claire Dulcire,
Dirk d'Hooge,
André Herchuelz,
Preview
|
PDF (523KB)
|
|
摘要:
In a double-blind, placebo-controlled, crossover study, the effects of therapeutic doses of the new tricyclic antidepressant tianeptine on cardiovascular function were closely monitored in 21 healthy volunteers during a 2-week treatment period. Blood pressure measurements, ECG recording, 24-h Holter monitoring, and echocardiography were carried out at 1-week intervals. Isotopic ventriculography was measured twice under each treatment. Tianeptine did not produce orthostatic hypotension or increase heart rate. No ECG changes could be observed and the cardiac conduction time remained unchanged. One subject presented with an increase in frequency of ventricular premature beats that could not be definitely attributed to the drug. Cardiac output assessed at rest and after a bicycle exercise stress test was not altered. The present study suggests that tianeptine is a tricyclic antidepressant endowed with less cardiac toxicity than classical tricyclic antidepressants.
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
6. |
Influence of Tetrahydro‐9-Aminoacridine on Excitatory Amino Acid Release |
|
Clinical Neuropharmacology,
Volume 13,
Issue 1,
1990,
Page 58-66
Alan Palmer,
Janet Steele,
Stephen Lowe,
David Bowen,
Preview
|
PDF (469KB)
|
|
摘要:
Alzheimer's disease may be associated with an early and clinically relevant degeneration of some cortical excitatory amino acid-releasing neurons. Tetrahydro-9-aminoacridine (tacrine) might be an effective drug for the treatment of the disease. Various pharmacological paradigms (in rats) related to amino acid release are shown here to be modified both in vivo and in vitro by the drug. These effects are only observed with high concentrations, so it is unlikely that tacrine acts through amino acid release in humans.
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
7. |
Primidone in the Long‐Term Treatment of Essential TremorA Prospective Study with Computerized Quantitative Analysis |
|
Clinical Neuropharmacology,
Volume 13,
Issue 1,
1990,
Page 67-76
Enrico Sasso,
Emilio Perucca,
Roberto Fava,
Stefano Calzetti,
Preview
|
PDF (475KB)
|
|
摘要:
The long-term efficacy of primidone (375–750 mg/day) in essential tremor was evaluated prospectively in 11 patients who had shown a favorable response to 4-week treatment with the drug under placebo-controlled conditions. On accelerometric evaluation, the magnitude of tremor after 3,6, and 12 months on primidone was still significantly reduced compared with the initial placebo period. After discontinuation of primidone, tremor amplitude reverted to the placebo levels. Some loss of efficacy during long-term administration, however, was suggested by the results of self-assessment, physician's assessment, and performance tests. Three patients discontinued prematurely the drug because the sedative effects outweighed the potential therapeutic benefit. Side effects (especially drowsiness and sedation) were common at 4 weeks and 3 months but tended to subside thereafter. It is concluded that primidone retains at least part of its tremorolytic effect for up to 1 year, although the overall clinical benefit is limited in most patients.
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
8. |
Treatment of Tourette's Syndrome with Calcium Antagonists |
|
Clinical Neuropharmacology,
Volume 13,
Issue 1,
1990,
Page 77-83
F. Micheli,
M. Gatto,
E. Lekhuniec,
C. Mangone,
M. Pardal,
R. Pikielny,
I. Parera,
Preview
|
PDF (363KB)
|
|
摘要:
Six males and one female with chronic tic disorders, whose ages ranged from 12 to 31 years, were evaluated before treatment, after 1 month on placebo, after a single 10 mg nifedipine dose (three patients), and monthly while on flunarizine 10–15 mg (mean dose of 13 mg). None of the patients receiving nifedipine improved, but treatment with flunarizine significantly decreased both motor and phonic tic severity and frequency in all but one patient. Side effects included mild transient headaches in one patient, depression in one, and bradykinesia in two. Although a double-blind study is essential to validate our findings, results suggest that flunarizine is a useful drug in the treatment of Gilles de la Tourette syndrome.
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
9. |
Effects of Long‐Term Amantadine Treatment on Clinical Symptoms and EEG of a Patient in a Vegetative State |
|
Clinical Neuropharmacology,
Volume 13,
Issue 1,
1990,
Page 84-88
Jun Horiguchi,
Yasushi Inami,
Taka'aki Shoda,
Preview
|
PDF (273KB)
|
|
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
10. |
Announcement |
|
Clinical Neuropharmacology,
Volume 13,
Issue 1,
1990,
Page 89-89
Preview
|
PDF (24KB)
|
|
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
|